Physician profile
Jason Michael Harmon
NPI 1356339295
$7,053.12
in general payments reported to CMS, 2019-2025
46 companies · $1,952 in 2025
The $1,952 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.47 · 2020: $17.12 · 2021: $356 · 2022: $1,146 · 2023: $1,392 · 2024: $2,106 · 2025: $1,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,449.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,362.53 | 2021-2025 | |
| Novo Nordisk INC | $846.36 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $707.87 | 2021-2025 | |
| Abbvie INC. | $632.14 | 2021-2025 | |
| Abbott Laboratories | $475.33 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $466.94 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $376.13 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $322.45 | 2023-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $237.22 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.19 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.04 | 2021-2025 | Jardiance |
| Eisai INC. | $106.78 | 2021-2024 | |
| Exact Sciences Corporation | $100.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $89.70 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Merit Medical Systems INC | $69.58 | 2025 | Esophyx |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.